

Leo Rasche

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6958610/publications.pdf>

Version: 2024-02-01

78
papers

2,379
citations

185998

28
h-index

233125

45
g-index

81
all docs

81
docs citations

81
times ranked

3076
citing authors

#	ARTICLE	IF	CITATIONS
1	Transient regulatory T-cell targeting triggers immune control of multiple myeloma and prevents disease progression. <i>Leukemia</i> , 2022, 36, 790-800.	3.3	22
2	Salvage therapy with daratumumab in heavily pretreated, high-risk, proliferative, relapsed/refractory multiple myeloma. <i>Hematological Oncology</i> , 2022, 40, 202-211.	0.8	9
3	Tumour Escape from CAR-T Cells. , 2022, , 15-22.		4
4	Extramedullary disease in multiple myeloma: a systematic literature review. <i>Blood Cancer Journal</i> , 2022, 12, 45.	2.8	57
5	Minimal residual disease and imaging-guided consolidation strategies in newly diagnosed and relapsed refractory multiple myeloma. <i>British Journal of Haematology</i> , 2022, 198, 515-522.	1.2	7
6	Halting the vicious cycle within the multiple myeloma ecosystem: blocking JAM-A on bone marrow endothelial cells restores angiogenic homeostasis and suppresses tumor progression. <i>Haematologica</i> , 2021, 106, 1943-1956.	1.7	46
7	COVID-19 infection in patients with multiple myeloma: a German-Chinese experience from Würzburg and Wuhan. <i>Annals of Hematology</i> , 2021, 100, 843-846.	0.8	1
8	Improved Primary Staging of Marginal-Zone Lymphoma by Addition of CXCR4-Directed PET/CT. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1415-1421.	2.8	38
9	Elotuzumab for the treatment of extramedullary myeloma: a retrospective analysis of clinical efficacy and SLAMF7 expression patterns. <i>Annals of Hematology</i> , 2021, 100, 1537-1546.	0.8	7
10	Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma. <i>Nature Medicine</i> , 2021, 27, 616-619.	15.2	140
11	Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations. <i>British Journal of Haematology</i> , 2021, 194, 496-507.	1.2	67
12	The mutagenic impact of melphalan in multiple myeloma. <i>Leukemia</i> , 2021, 35, 2145-2150.	3.3	32
13	Management of patients with difficult-to-treat multiple myeloma. <i>Future Oncology</i> , 2021, 17, 2089-2105.	1.1	1
14	Cereblon enhancer methylation and IMiD resistance in multiple myeloma. <i>Blood</i> , 2021, 138, 1721-1726.	0.6	25
15	Novel immunotherapies in multiple myeloma – chances and challenges. <i>Haematologica</i> , 2021, 106, 2555-2565.	1.7	21
16	Single- and double-hit events in genes encoding immune targets before and after T cell-engaging antibody therapy in MM. <i>Blood Advances</i> , 2021, 5, 3794-3798.	2.5	30
17	Beverages intake and functional bowel disorders: A cross-sectional study in first-year undergraduates. <i>Journal of Digestive Diseases</i> , 2021, 22, 630-636.	0.7	0
18	Is PFS the Right Endpoint to Assess Outcome of Maintenance Studies in Multiple Myeloma? Results of a Patient Survey Highlight Quality-of-Life As an Equally Important Outcome Measure. <i>Blood</i> , 2021, 138, 836-836.	0.6	6

#	ARTICLE	IF	CITATIONS
19	Obinutuzumab and venetoclax induced complete remission in a patient with ibrutinib-resistant non-nodal leukemic mantle cell lymphoma. <i>European Journal of Haematology</i> , 2020, 104, 352-355.	1.1	6
20	A review on tumor heterogeneity and evolution in multiple myeloma: pathological, radiological, molecular genetics, and clinical integration. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 476, 337-351.	1.4	30
21	Daratumumab in high-risk relapsed/refractory multiple myeloma patients: adverse effect of chromosome 1q21 gain/amplification and GEP70 status on outcome. <i>British Journal of Haematology</i> , 2020, 189, 67-71.	1.2	35
22	<i>CIC</i> Mutation as a Molecular Mechanism of Acquired Resistance to Combined BRAF-MEK Inhibition in Extramedullary Multiple Myeloma with Central Nervous System Involvement. <i>Oncologist</i> , 2020, 25, 112-118.	1.9	39
23	What is the future of immunotherapy in multiple myeloma?. <i>Blood</i> , 2020, 136, 2491-2497.	0.6	22
24	Clinical characteristics and outcome of multiple myeloma patients with concomitant COVID-19 at Comprehensive Cancer Centers in Germany. <i>Haematologica</i> , 2020, 105, 2872-2878.	1.7	40
25	Toxicities of Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma: An Overview of Experience From Clinical Trials, Pathophysiology, and Management Strategies. <i>Frontiers in Immunology</i> , 2020, 11, 620312.	2.2	21
26	IKZF1/3 and CRL4 ^{CRBN} E3 ubiquitin ligase mutations and resistance to immunomodulatory drugs in multiple myeloma. <i>Haematologica</i> , 2020, 105, e237-e241.	1.7	41
27	Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab (â€œPomâ€PADâ€Daraâ€) in relapsed/refractory multiple myeloma. <i>Cancer Medicine</i> , 2020, 9, 5819-5826.	1.3	10
28	Carfilzomib Based Treatment Strategies in the Management of Relapsed/Refractory Multiple Myeloma with Extramedullary Disease. <i>Cancers</i> , 2020, 12, 1035.	1.7	28
29	Sequential CD38 monoclonal antibody retreatment leads to deep remission in a patient with relapsed/refractory multiple myeloma. <i>International Journal of Immunopathology and Pharmacology</i> , 2020, 34, 205873842098025.	1.0	1
30	Real-World Experience with Minimal Residual Disease Testing with Next Generation Flow Cytometry and Functional Imaging in Multiple Myeloma. <i>Blood</i> , 2020, 136, 17-18.	0.6	0
31	The use of bispecific antibodies to optimize the outcome of patients with acute leukemia, lymphoma and multiple myeloma after SCT. <i>Bone Marrow Transplantation</i> , 2019, 54, 721-726.	1.3	12
32	Lack of Spleen Signal on Diffusion Weighted MRI is associated with High Tumor Burden and Poor Prognosis in Multiple Myeloma: A Link to Extramedullary Hematopoiesis?. <i>Theranostics</i> , 2019, 9, 4756-4763.	4.6	12
33	Response to daratumumab in rituximab-resistant EBV-associated PTLD following allogeneic stem cell transplantation from an EBV seronegative donor. <i>Leukemia and Lymphoma</i> , 2019, 60, 3573-3576.	0.6	10
34	The Impact of Tumor Heterogeneity on Diagnostics and Novel Therapeutic Strategies in Multiple Myeloma. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1248.	1.8	54
35	Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients. <i>Haematologica</i> , 2019, 104, 1440-1450.	1.7	67
36	Comparison of 11C-Choline and 11C-Methionine PET/CT in Multiple Myeloma. <i>Clinical Nuclear Medicine</i> , 2019, 44, 620-624.	0.7	30

#	ARTICLE	IF	CITATIONS
37	Functionally Defective T Cells After Chemotherapy of B-Cell Malignancies Can Be Activated by the Tetravalent Bispecific CD19/CD3 Antibody AFM11. <i>Journal of Immunotherapy</i> , 2019, 42, 180-188.	1.2	17
38	Adhesion-Mediated Multiple Myeloma (MM) Disease Progression: Junctional Adhesion Molecule a Enhances Angiogenesis and Multiple Myeloma Dissemination and Predicts Poor Survival. <i>Blood</i> , 2019, 134, 855-855.	0.6	7
39	Mechanisms of Proteasome Inhibitor Resistance Selected By Clonal Evolution in Multiple Myeloma. <i>Blood</i> , 2019, 134, 4349-4349.	0.6	4
40	RAC1 Inhibitor EHT1864 and Venetoclax Overcome Midostaurin Resistance in Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 1277-1277.	0.6	1
41	Kinase domain activation through gene rearrangement in multiple myeloma. <i>Leukemia</i> , 2018, 32, 2435-2444.	3.3	26
42	Treatment to suppression of focal lesions on positron emission tomography-computed tomography is a therapeutic goal in newly diagnosed multiple myeloma. <i>Haematologica</i> , 2018, 103, 1047-1053.	1.7	47
43	Expression of programmed death-1 on lymphocytes in myeloma patients is lowered during lenalidomide maintenance. <i>Haematologica</i> , 2018, 103, e126-e129.	1.7	28
44	The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma. <i>Blood</i> , 2018, 132, 59-66.	0.6	75
45	Maintaining therapeutic progress in multiple myeloma by integrating genetic and biological advances into the clinic. <i>Expert Review of Hematology</i> , 2018, 11, 513-523.	1.0	8
46	Profiling of Oncogenic Signaling in Multiple Myeloma – Association with Biology, Disease Progression and Prognosis. <i>Blood</i> , 2018, 132, 3206-3206.	0.6	1
47	Combination of Flow Cytometry and Functional Imaging for Monitoring of Residual Disease in Myeloma. <i>Blood</i> , 2018, 132, 3185-3185.	0.6	0
48	Lack of a Spleen Signal on Diffusion Weighted MRI Is Associated with High Tumor Burden and Poor Prognosis in Multiple Myeloma. <i>Blood</i> , 2018, 132, 4471-4471.	0.6	0
49	Immunologic approaches for the treatment of multiple myeloma. <i>Cancer Treatment Reviews</i> , 2017, 55, 190-199.	3.4	46
50	Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma. <i>Blood</i> , 2017, 130, 30-34.	0.6	180
51	The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype. <i>Haematologica</i> , 2017, 102, e313-e316.	1.7	26
52	The level of deletion 17p and bi-allelic inactivation of <i>TP53</i> has a significant impact on clinical outcome in multiple myeloma. <i>Haematologica</i> , 2017, 102, e364-e367.	1.7	57
53	Where are we now with the treatment of multiple myeloma?. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 461-462.	12.5	11
54	The varied distribution and impact of <i>RAS</i> codon and other key DNA alterations across the translocation cyclin D subgroups in multiple myeloma. <i>Oncotarget</i> , 2017, 8, 27854-27867.	0.8	25

#	ARTICLE	IF	CITATIONS
55	“Real-life”™ experience of preapproval carfilzomib-based therapy in myeloma – analysis of cardiac toxicity and predisposing factors. <i>European Journal of Haematology</i> , 2016, 97, 25-32.	1.1	68
56	Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice. <i>American Journal of Hematology</i> , 2016, 91, 575-580.	2.0	83
57	Characteristics and outcomes of patients with multiple myeloma aged 21–40 years versus 41–60 years: a multi-institutional case-control study. <i>British Journal of Haematology</i> , 2016, 175, 884-891.	1.2	21
58	Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma. <i>Blood</i> , 2016, 128, 1735-1744.	0.6	170
59	A GRP78-Directed Monoclonal Antibody Recaptures Response in Refractory Multiple Myeloma with Extramedullary Involvement. <i>Clinical Cancer Research</i> , 2016, 22, 4341-4349.	3.2	43
60	Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Focus on Longitudinal Assessment of Donor Chimerism, Extramedullary Disease, and High-Risk Cytogenetic Features. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1988-1996.	2.0	40
61	Cutaneous involvement in multiple myeloma: a multi-institutional retrospective study of 53 patients. <i>Leukemia and Lymphoma</i> , 2016, 57, 2071-2076.	0.6	30
62	Extensive Regional Intra-Clonal Heterogeneity in Multiple Myeloma - Implications for Diagnostics, Risk Stratification and Targeted Treatment. <i>Blood</i> , 2016, 128, 3278-3278.	0.6	2
63	The Clinical Impact of Macrofocal Disease in Multiple Myeloma Differs Between Presentation and Relapse. <i>Blood</i> , 2016, 128, 4431-4431.	0.6	8
64	Daratumumab Single Agent and Daratumumab Plus Pomalidomide and Dexametasone in Relapsed/Refractory Multiple Myeloma: A Real Life Retrospective Evaluation. <i>Blood</i> , 2016, 128, 4516-4516.	0.6	8
65	A Survey of Fusion Genes in Myeloma Identifies Kinase Domain Activation Which Could be Targeted with Available Treatments. <i>Blood</i> , 2016, 128, 117-117.	0.6	1
66	Next Generation Sequencing (NGS) Based Minimal Residual Disease (MRD) Testing Is Highly Predictive of Overall and Progression Free Survival in the Total Therapy Trials and Shows Different Prognostic Implications in High Vs Standard Risk Multiple Myeloma. <i>Blood</i> , 2016, 128, 2064-2064.	0.6	0
67	Spatial-Temporal Genomic Analyses Reveal a Component of "Big Bang" Kinetics in Multiple Myeloma Evolution. <i>Blood</i> , 2016, 128, 239-239.	0.6	3
68	High Risk Myeloma Is Characterized By the Bi-Allelic Inactivation of CDKN2C and RB1. <i>Blood</i> , 2016, 128, 4416-4416.	0.6	1
69	GRP78-directed immunotherapy in relapsed or refractory multiple myeloma - results from a phase 1 trial with the monoclonal immunoglobulin M antibody PAT-SM6. <i>Haematologica</i> , 2015, 100, 377-384.	1.7	64
70	Targeted sequencing using a 47 gene multiple myeloma mutation panel (M ^{>3} /P) in 17p high risk disease. <i>British Journal of Haematology</i> , 2015, 168, 507-510.	1.2	42
71	Primary bone marrow diffuse large B-cell lymphoma affecting distal parts of the legs as a cause of persisting B symptoms. <i>European Journal of Haematology</i> , 2014, 93, 545-546.	1.1	3
72	The lymphoma-like polychemotherapy regimen “Dexa-BEAM” in advanced and extramedullary multiple myeloma. <i>Annals of Hematology</i> , 2014, 93, 1207-1214.	0.8	29

#	ARTICLE	IF	CITATIONS
73	Crucial Role of Regulatory T Cells in Predicting the Outcome of the T Cell Engaging Antibody Blinatumomab in Relapsed and Refractory B Precursor ALL Patients. <i>Blood</i> , 2014, 124, 2291-2291.	0.6	9
74	The Natural Human IgM Antibody PAT-SM6 Induces Apoptosis in Primary Human Multiple Myeloma Cells by Targeting Heat Shock Protein GRP78. <i>PLoS ONE</i> , 2013, 8, e63414.	1.1	53
75	Features of extramedullary myeloma relapse: high proliferation, minimal marrow involvement, adverse cytogenetics: a retrospective single-center study of 24 cases. <i>Annals of Hematology</i> , 2012, 91, 1031-1037.	0.8	82
76	Cellular therapy to control tumor progression. <i>Current Opinion in Hematology</i> , 2009, 16, 437-443.	1.2	12
77	Laparoscopic Insertion with Tip Suturing, Omentectomy, and Ovariopexy Improves Lifespan of Peritoneal Dialysis Catheters in Children. <i>Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A</i> , 2008, 18, 302-305.	0.5	22
78	The human IgM antibody SAM-6 induces tumor-specific apoptosis with oxidized low-density lipoprotein. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 326-333.	1.9	51